American International Group Inc. lowered its stake in shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 0.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,421 shares of the biopharmaceutical company’s stock after selling 111 shares during the quarter. American International Group Inc.’s holdings in Intercept Pharmaceuticals were worth $1,453,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Intercontinental Wealth Advisors LLC purchased a new position in Intercept Pharmaceuticals in the 4th quarter worth $34,000. Advisor Group Inc. raised its position in Intercept Pharmaceuticals by 63.5% in the 4th quarter. Advisor Group Inc. now owns 739 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 287 shares during the period. Strs Ohio raised its position in Intercept Pharmaceuticals by 30.0% in the 4th quarter. Strs Ohio now owns 1,300 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 300 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Intercept Pharmaceuticals by 14.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,416 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 183 shares during the period. Finally, Stifel Financial Corp purchased a new position in Intercept Pharmaceuticals in the 4th quarter worth $228,000. Hedge funds and other institutional investors own 70.24% of the company’s stock.
A number of equities analysts recently commented on the stock. Wedbush reiterated a “buy” rating and issued a $251.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, March 27th. BidaskClub cut shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th. B. Riley set a $169.00 target price on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, April 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $191.00 target price (up previously from $170.00) on shares of Intercept Pharmaceuticals in a research report on Thursday, February 28th. Finally, Citigroup raised their price target on shares of Intercept Pharmaceuticals from $106.00 to $140.00 and gave the stock a “neutral” rating in a report on Thursday, February 21st. Two analysts have rated the stock with a sell rating, six have given a hold rating and sixteen have given a buy rating to the company’s stock. Intercept Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $144.05.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, February 28th. The biopharmaceutical company reported ($2.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.42) by ($0.55). The company had revenue of $53.30 million for the quarter, compared to the consensus estimate of $52.53 million. Intercept Pharmaceuticals had a negative net margin of 172.39% and a negative return on equity of 592.58%. The company’s revenue for the quarter was up 41.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($4.43) EPS. As a group, sell-side analysts expect that Intercept Pharmaceuticals Inc will post -9.13 earnings per share for the current fiscal year.
In other news, insider David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $111.51, for a total transaction of $223,020.00. Following the sale, the insider now owns 42,543 shares of the company’s stock, valued at approximately $4,743,969.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Srinivas Akkaraju sold 23,438 shares of Intercept Pharmaceuticals stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $128.78, for a total transaction of $3,018,345.64. The disclosure for this sale can be found here. Insiders have sold a total of 32,504 shares of company stock worth $3,969,947 in the last ninety days. Insiders own 4.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: “American International Group Inc. Sells 111 Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT)” was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/american-international-group-inc-sells-111-shares-of-intercept-pharmaceuticals-inc-icpt.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.